New hope for kidney disease patients: managed access to EXV811, atrasentan
NCT ID NCT07319585
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides access to EXV811, atrasentan for people with IgA nephropathy, a serious kidney disease. It is for patients who have no other treatment options and cannot join a clinical trial. The goal is to offer potential benefit when standard therapies are not available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mapping the Real-World treatment landscape for IgA nephropathy
- A simple test could forecast kidney disease progression
- Experimental drug aims to protect kidneys in inflammatory diseases
- Scientists probe kidney cell metabolism to unlock secrets of ANCA vasculitis
- Immune cell therapy takes on kidney disease
- Steroids for kidney disease: do they prevent failure Long-Term?